-
Product Insights
NewAdrenal Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Adrenal Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms...
-
Product Insights
NewAdrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024
Empower your strategies with our Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female sex, hereditary disease that affects the adrenal glands, age, and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in...
-
Company Insights
The Emirates Group – Digital Transformation Strategies
Emirates Digital Transformation Strategies Overview Emirates is leveraging several emerging technologies as a part of its digital transformation strategies. The annual ICT spending of Emirates was estimated at $819 million in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. The Emirates Group (Emirates Group) provides domestic, regional, and international air transportation services. The company’s other operations include wholesale and retail of consumer goods, food and beverage sales, and hotel...
-
Product Insights
Drug Eluting Stents (DES) Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Drug Eluting Stents (DES) Pipeline Market Report Overview Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The Drug Eluting Stents (DES) pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Ovarian Cancer Drug Details: IPI-549 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Metastatic Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Metastatic Ovarian Cancer Drug Details: IPI-549 is under development for the treatment of...
-
Product Insights
NewNet Present Value Model: Infinity Pharmaceuticals Inc’s IPI-549 + Opdivo
Empower your strategies with our Net Present Value Model: Infinity Pharmaceuticals Inc's IPI-549 + Opdivo report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: IPI-549 is under development for the...